Drug Combination Details
| General Information of the Combination (ID: C58550) | |||||
|---|---|---|---|---|---|
| Name | Roxithromycin NP Info | + | Cyclophosphamide Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Pulmonary hypertension
[ICD-11: BB01]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ABCB1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | P388 | CVCL_7222 | Mouse lymphoma | Mus musculus | ||
| Experimental
Result(s) |
The combination cyclophosphamide and roxithromycin, but not the individual compounds, is toxic to endothelial cells by inducing apoptosis. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Mechanisms of venoocclusive disease resulting from the combination of cyclophosphamide and roxithromycin. Ther Drug Monit. 2006 Dec;28(6):766-74. | |||
